Article
CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Thoracic cancer - 1 Jun 2020
Zhang Kun, Wang Lili, Wei Aili, Jia Xinfei, Liu Xiaoqing
Abstract excerpt
BACKGROUND: CM082 is a novel angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). The purpose of this research was to evaluate the antitumor activity of CM082 combined with gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) in vitro and in vivo. METHODS: The effect of CM082 on human...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.